Merck highlights subcutaneous demand even as Keytruda sales soar

Mer­ck said Keytru­da sales jumped 21% to $6.6 bil­lion in the fourth quar­ter of the year, dri­ven by new ap­provals in ear­li­er-stage in­di­ca­tions for breast can­cer and re­nal cell car­ci­no­ma, and more de­mand in metasta­t­ic can­cers.

The com­pa­ny’s crown jew­el made up near­ly half of its rev­enue in the fi­nal three months of the year.

The block­buster scored mul­ti­ple ap­provals last year, in­clud­ing in com­bi­na­tion with Astel­las and Pfiz­er’s Pad­cev for first-line treat­ment of urothe­lial can­cer; with chemora­dio­ther­a­py for a spe­cif­ic late-stage cer­vi­cal can­cer; as a first-line treat­ment for HER2-neg­a­tive gas­tric can­cer; and in com­bi­na­tion with gem­c­itabine and cis­platin for bil­iary tract can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.